<?xml version="1.0" encoding="UTF-8"?>
<p id="p0140">Telbivudine (L-thymidine) is used in the treatment of hepatitis B infection. Clinical trials have shown that this drug is significantly more effective than lamivudine and less likely to cause resistance. Moreover, telbivudine has some pleiotropic immunomodulatory and anti-inflammatory properties (
 <xref rid="bib84" ref-type="bibr">Rehermann and Bertoletti, 2015</xref>). Recently, it was shown that telbivudine confers endothelial-protective effects on B19V-infected endothelial cells and improves the chronic myocarditis associated with B19V transcriptional activity (
 <xref rid="bib102" ref-type="bibr">Van Linthout et al., 2018</xref>).
</p>
